Nuformix (LON:NFX) Trading Down 11.1% – Here’s What Happened

Nuformix plc (LON:NFX) traded down 11.1% during mid-day trading on Thursday . The stock traded as low as GBX 0.24 and last traded at GBX 0.24. 8,196,036 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 36,088,453 shares. The stock had previously closed at GBX 0.27.

Nuformix Price Performance

The company has a fifty day moving average price of GBX 0.26 and a 200 day moving average price of GBX 0.23. The company has a market cap of £5.27 million, a PE ratio of -6.36 and a beta of 1.22.

Nuformix (LON:NFX) last announced its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) EPS for the quarter.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.